REPEAT: M Pharmaceutical Enters Into Letter of Intent to Acquire Reformulated Orlistat for Weight Loss from Chelatexx, LLC
- Acquisition would add a novel weight loss product to M Pharma's pipeline - C-103 is a patented reformulation of FDA-approved orlistat (Xenical(R) and alli(R)) - Chelatexx asset acquisition part of a comprehensive reorganization of M Pharmaceutical to …